Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

4(44.4%)

9Total

Phase 1(5)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04055454Phase 1Completed

A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Role: lead

NCT03807843Phase 2Completed

Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

Role: lead

NCT02996890Phase 1Completed

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

Role: lead

NCT04497298Phase 1Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine

Role: collaborator

NCT04033068Phase 1Completed

Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)

Role: lead

NCT02861586Phase 2Completed

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine

Role: lead

NCT03635086Phase 2Completed

Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)

Role: lead

NCT03101111Phase 2Completed

Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area

Role: lead

NCT04195373Phase 1Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Role: lead

All 9 trials loaded